Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS p.Gly12Ala (p.G12A)
(
ENST00000256078.10,
ENST00000311936.8,
ENST00000556131.2,
ENST00000557334.6,
ENST00000685328.1,
ENST00000686969.1,
ENST00000688940.1,
ENST00000692768.1,
ENST00000693229.1 )
KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) - Associated Disease
- multiple myeloma
- Source Database
- CIViC Evidence
- Description
- In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2009
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/148
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Multiple Myeloma
- Evidence Direction
- Supports
- Drug
- Melphalan
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 19284554
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Melphalan | Resitance or Non-Reponse | true |